|Videos|January 31, 2021
Glaukos COO shares product updates, 2021 pipeline
Author(s)David Hutton, Alex Delaney-Gesing
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
What changed in glaucoma care in 2025: Surgeon perspective
3
Achieving a new level of refractive precision: Surgical strategies
4
Global trial equity: How LMIC data is reshaping US ophthalmology research
5